This site is
intended for
US audiences only.
That’s why Celgene Patient Support® is ready to help answer questions about the insurance approval process. And you may need help paying for REVLIMID. Celgene Patient Support® can help you and your loved ones understand the programs and services available to you.
Programs that help with the cost of REVLIMID differ by the type of insurance you have. Even if you don’t have insurance or enough coverage to pay for your medicine, financial help may be available.
Commercial insurance
If you have commercial insurance, you may qualify for the Celgene Commercial Co-pay Program.
Eligibility criteria include*
Medicare, Medicaid, or other government-sponsored insurance
Your Specialist can provide you with information about independent third-party organizations† that may be able to help with the cost of your:
I do not have health insurance or enough coverage to pay for REVLIMID
If you do not have health insurance or enough coverage to pay for your medicine, you may qualify for the Celgene Patient Assistance Program (PAP)‡
*
Other eligibility requirements and restrictions apply. Please see full Terms and Conditions
†
Financial and medical eligibility requirements vary by organization
‡
Patients must meet specified financial and eligibility requirements to qualify for assistance.
PATIENTS MUST MEET THE FOLLOWING CRITERIA TO ENROLL:
PROGRAM BENEFITS
PROGRAM TIMING
ADDITIONAL TERMS AND CONDITIONS OF THE
CELGENE COMMERCIAL CO-PAY PROGRAM
REVLIMID® (lenalidomide) is a prescription medicine, used to treat people with mantle cell lymphoma (MCL) when the disease comes back or becomes worse after treatment with two prior medicines, one of which included bortezomib. MCL is a cancer of a type of white blood cell called lymphocytes that are in the lymph nodes
REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial
It is not known if REVLIMID is safe and effective in children
Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide
TO REPORT SUSPECTED ADVERSE REACTIONS OR EMBRYO-FETAL EXPOSURE: CONTACT CELGENE CORPORATION AT 1-888-423-5436 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH
REVLIMID® (lenalidomide) is a prescription medicine, used to treat people with mantle cell lymphoma (MCL) when the disease comes back or becomes worse after treatment with two prior medicines, one of which included bortezomib. MCL is a cancer of a type of white blood cell called lymphocytes that are in the lymph nodes
REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial
It is not known if REVLIMID is safe and effective in children
Before you begin taking REVLIMID, you must read and agree to all of the instructions in the REVLIMID REMS® program. Before prescribing REVLIMID, your healthcare provider will explain the REVLIMID REMS program to you and have you sign the Patient-Physician Agreement Form
REVLIMID may cause serious side effects; including:
Call your healthcare provider or get medical help right away if you get any of the following during treatment with REVLIMID:
Before you take REVLIMID, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. REVLIMID and other medicines may affect each other, causing serious side effects. Talk with your healthcare provider before taking any new medicines. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist
Take REVLIMID exactly as prescribed and follow all the instructions of the REVLIMID REMS program
REVLIMID can cause serious side effects, including:
The most common side effects of REVLIMID include:
These are not all the possible side effects of REVLIMID. Your healthcare provider may tell you to decrease your dose, temporarily stop or permanently stop taking REVLIMID if you develop certain serious side effects during treatment with REVLIMID. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088
Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide
My Moments, My Support is a new program for people who are taking REVLIMID for
multiple myeloma or for people who want more information about REVLIMID.
Join now to receive your REVLIMID Treatment Overview Brochure.
If you or a loved one are currently on REVLIMID and would like a Patient Starter Kit, please check the box to request a Kit when you enroll.
When you enroll in Celgene Patient Support®, you and your family can count on free, personal help with:
• Finding financial help to pay for REVLIMID
• Understanding your insurance plan
• Locating help with travel costs to and from your doctor's office
Celgene Patient Support
1-800-931-8691
(M-F, 8 am-7 pm ET)
www.CelgenePatientSupport.com
Receive e-mails featuring content about
what to expect with REVLIMID.
Learn more about multiple
myeloma.
REVLIMID® (lenalidomide) is a prescription medicine, used to treat people with mantle cell lymphoma
Before you begin taking REVLIMID, you must read and agree to all of the instructions in the REVLIMID REMS® program. Before prescribing REVLIMID,
This website is intended for
US healthcare professionals only.
Complete the form fields below to share this page.
Your e-mail was sent.
Close
THIS SITE IS INTENDED FOR US AUDIENCES ONLY.